Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Neurologic Disorders: early-phase trial registry

5 of 6 indexed Neurologic Disorders trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 5 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Neurologic Disorders: 6 US clinical trials tracked, 5 recruiting.

Neurologic Disorders is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Thomas Advanced Medical, running 1 of these trials.

Enrollment posture brief

Registry condition neurologic-disorders

OPEN 5 | RECR 83% | LATE 0 | EARLY 1 | RANK #2866 | SPON 1

Nearest open-share peer: Alcoholic Hepatitis (83% recruiting · 6 trials)

Neurologic Disorders (this)83%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Neurologic Disorders

Neurologic Disorders lists 5 open slots (83% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neurologic Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neurologic Disorders is recruiting above its size-band peers.

    5 of 6 indexed trials (83.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Neurologic Disorders research.

    Thomas Advanced Medical accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Neurologic Disorders enrolment sits around 5,000 participants.

    Median target enrolment is 5,000 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.

  4. Neurologic Disorders research leans observational.

    2 interventional and 4 observational studies make up this index (33.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Neurologic Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PrimePro™/ PrimeMSK™ Biological
1 trials
Radiological exams Procedure
1 trials
Laboratory tests Procedure
1 trials
Intravenous and Intranasal BMSC Procedure
1 trials
Interview Other
1 trials

US sites by state

Facility locations filed on Neurologic Disorders trials. A trial with sites in several states counts in each.

Maryland 2 trials
Wisconsin 1 trials
Texas 1 trials
Florida 1 trials
Connecticut 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neurologic Disorders page

6 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurologic Disorders condition card totals 6 registered trials; most-linked intervention PrimePro™/ PrimeMSK™; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.